Completed PHASE3 INTERVENTIONAL NCT00448955

Open-Label Study of ARD-0403 in Testosterone Deficient Men

A Phase III Open-Label Study of the Efficacy and Safety of ARD-0403, a Testosterone Cream, in Testosterone Deficient Men

Sponsor: Ardana Bioscience Ltd

Conditions Hypogonadism

Interventions ARD-0403

Updated 5 times since 2017 Last updated: Apr 17, 2008 Started: May 31, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00448955, this PHASE3 trial focuses on Hypogonadism and remains completed. Sponsored by Ardana Bioscience Ltd, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ardana Bioscience Ltd

Data source: Ardana Bioscience Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Chicago, United States , Durham, United States , Houston, United States , Huntsville, United States , Philadelphia, United States , Portland, United States , San Antonio, United States , Seattle, United States and 2 more locations